Evaluation of <sup>153</sup>Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy

TANG Zhaobing; et al

您当前的位置：

首页 >

文章列表页 >

Evaluation of ¹⁵³Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy

更新时间：2024-01-17

- Evaluation of ¹⁵³Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy
- Journal of Chongqing Medical University Issue 3, Pages: 417-418(2006)
- 作者机构：
  
  1. 重庆医科大学附属第一医院泌尿外科
  2. 重庆医科大学附属第一医院泌尿外科,重庆,400016
- 作者简介：
- 基金信息：
- DOI：
  CLC： R737.25
- Published：2006，
扫描看全文
[1]汤召兵,陈在贤,刘朝东,刘航,王德林.~(153)Sm-EDTMP治疗前列腺癌内分泌治疗后骨转移骨痛的效果评价[J].重庆医科大学学报,2006(03):417-418+421.

TANG Zhaobing, et al. Evaluation of ¹⁵³Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy. [J]. Journal of Chongqing Medical University (3):417-418(2006)
[1]汤召兵,陈在贤,刘朝东,刘航,王德林.~(153)Sm-EDTMP治疗前列腺癌内分泌治疗后骨转移骨痛的效果评价[J].重庆医科大学学报,2006(03):417-418+421. DOI：

TANG Zhaobing, et al. Evaluation of ¹⁵³Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy. [J]. Journal of Chongqing Medical University (3):417-418(2006) DOI：

摘要

目的:评价153Sm-EDTMP（153钐-乙二胺四甲撑膦酸）对前列腺癌患者行内分泌治疗后骨转移灶骨痛的治疗效果。方法:选择18例前列腺癌已行双侧睾丸切除术+口服福至尔治疗3～6个月、骨转移灶及骨痛未缓解患者

用153Sm-EDTMP治疗

153Sm-EDTMP用量为37MBq/kg体重.次

1次/月×（3～6）个月。密切观察骨痛缓解情况

治疗3个月后行骨扫描了解骨转移灶情况。结果:18例患者中14例骨痛有不同程度缓解

占77.8%

骨扫描示骨转移灶客观反应率为55.5%（10/18）。结论:对晚期前列腺癌、在行内分泌治疗后存在骨转移顽固性骨痛患者

153Sm-EDTMP内放射治疗仍有较好效果。

Abstract

Objective: To evaluate the effect of Samarium etramthylene phosphoric acid(153Sm-EDTMP) in the treatment of painful bony metastases from prostate cancer after hormone therapy.Methods: 18 patients after being treated with hormone therapy(excision of testes+flutamide) for 3~6 months and with painful bony metastases from prostate cancer were injected 153Sm-EDTMP(dosage:37MBq/kg)

After the patients underwent 1~3 dose treatment.The palliation of pain and change of bone metastases on bone scans were evaluated.Results: A significant decrease of bone pain was achieved

making up 77.8%(14/18) and X ray and bone radionuclide imaging exam showed that 2 patients achieved complete focus disappearance

and 8 patients achieved partial focus disappearance.The response rate is 55.5%.Conclusion: 153Sm-EDTMP radiotherapy is efficacious to the refractory painful bone metastases in prostate cancer.

关键词

前列腺癌骨转移骨痛153Sm-EDTMP内分泌治疗

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on affecting factors of breast Cancer bone metastasis

Initial identification of CD133 /CD44 prostate cancer stem cell through MACS

Related Author

李小放

shengxia

Related Institution

the First Affiliate Hospital of Chongqing Medical University

⁰

Evaluation of 153Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy

DOI：

摘要

Abstract

关键词

Keywords

references

Evaluation of ¹⁵³Sm-EDTMP Therapy for Metastasis Prostate Cancer and Pain due to Bony Metastases after Hormone Therapy